Head-to-head evidence
CardiAMP vs HS-001
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Heart Failure
Shared mechanism: Cardiac cell therapy · full Heart Failure pipeline
CardiAMP
Developed by BioCardia
NCT02438306 · Phase 3 · completed
The study randomized 125 participants to CardiAMP or a sham procedure and masked participants and outcome assessors. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: April 2027 · NCT06258447 (registry estimate)
HS-001
Developed by Heartseed
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CardiAMP's landscape · HS-001's landscape